Edition:
United States

Profile: Seattle Genetics Inc (SGEN.O)

SGEN.O on Nasdaq

63.86USD
20 Oct 2017
Change (% chg)

$-0.15 (-0.23%)
Prev Close
$64.01
Open
$65.00
Day's High
$65.15
Day's Low
$63.30
Volume
1,537,396
Avg. Vol
1,215,366
52-wk High
$75.36
52-wk Low
$45.31

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

Company Address

Seattle Genetics Inc

21823 30th Dr SE
BOTHELL   WA   98021-3907
P: +1425.5274000
F: +1425.5274001

Company Web Links